Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
Overview of main clinical studies for MASLD/MASH with GLP-1 receptor agonists and dual or triple agonists targeting glucagon/GIP/GLP-1 receptors Liraglutide Liraglutide, a once-daily GLP-1 receptor agonist with authorized indications for type 2 diabetes and obesity, was evaluated in the LEAN trial (NCT01237119), a phase 2 randomized controlled study enrolling 52 adults with biopsy-proven MASH [22]
doi: 10.1089/105072503322401032 10 ChoYMFujitaYKiefferTJ
Species 189198, (2016)
Read more lived-experience reflections in Reta Diary
US$ 25.37
US$ 21.91
US$ 24.51
US$ 25.67
US$ 29.33
US$ 22.58
